Translational potential of a mouse in vitro bioassay in predicting gastrointestinal adverse drug reactions in Phase I clinical trials

Neurogastroenterology and Motility

Volumn 26, Issue 7, 2014, Pages 980-989

  Keating, C ^a,c   Ewart, L ^b   Grundy, L ^a   Valentin, J P ^b,d   Grundy, David ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d UCB PHARMA   (Belgium)

Author keywords

Adverse drug reaction; Bioassay; Biomarker; Gastrointestinal motility; Safety pharmacology

Indexed keywords

2 CHLORO 3 (3,4 DICHLOROPHENYL) 1 ISOPROPYL 4 METHYLIMIDAZOLIUM CHLORIDE; CHARCOAL; CHEMICAL COMPOUND; COMPOUND C; COMPOUND D; COMPOUND G; COMPOUND H; COMPOUND I; COMPOUND J; COMPOUND M; COMPOUND N; COMPOUND R; COMPOUND T; COMPOUND Z; RIMONABANT; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

ADULT; ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; COLON MOTILITY; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERISTALSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; STOMACH EMPTYING; TEST MEAL; ANIMAL; CHEMICALLY INDUCED; COLON; DRUG EFFECTS; GASTROINTESTINAL TRANSIT; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; COLON; CONSTIPATION; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; IN VITRO TECHNIQUES; MICE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84903130484     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12349     Document Type: Article

References (28)

1. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, Valentin JP. Safety pharmacology-a progressive approach. Fundam Clin Pharmacol 2002; 16: 161-73.
2. Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV. Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol 1998; 54: 13-20.
3. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf 2000; 22: 53-72.
4. Gore RM, Levine MS, Ghahremani GG. Drug-induced disorders of the stomach and duodenum. Abdom Imaging 1999; 24: 9-16.
5. Lat I, Foster DR, Erstad B. Drug-induced acute liver failure and gastrointestinal complications. Crit Care Med 2010; 38: S175-87.
6. Ghahremani GG. Gastrointestinal complications of drug therapy. Abdom Imaging 1999; 24: 1-2.
7. Fung M. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Information Journal 2001; 35: 293-317.
8. Valentin JP, Kenna JG, Lainee P, Pollard CE, Redfern WS, Roberts S, Hammond T. A literature-based analysis of cardiovascular adverse events impacting on drug development. J Pharmacol Toxicol Methods 2012; 66: 173.
9. Peck RW. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov Today 2007; 12: 289-94.
10. Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 2008; 58: 77-87.
11. Harrison AP, Erlwanger KH, Elbrond VS, Andersen NK, Unmack MA. Gastrointestinal-tract models and techniques for use in safety pharmacology. J Pharmacol Toxicol Methods 2004; 49: 187-99.
12. Coupar IM, Lui L. A simple method for measuring the effects of drugs on intestinal longitudinal and circular muscle. J Pharmacol Toxicol Methods 1996; 36: 147-54.
13. Osinski MA, Seifert TR, Cox BF, Gintant GA. An improved method of evaluation of drug-evoked changes in gastric emptying in mice. J Pharmacol Toxicol Methods 2002; 47: 115-20.
14. Gremlich HU, Martínez V, Kneuer R, Kinzy W, Weber E, Pfannkuche HJ, Rudin M. Noninvasive assessment of gastric emptying by near-infrared fluorescence reflectance imaging in mice: pharmacological validation with tegaserod, cisapride, and clonidine. Mol Imaging 2004; 3: 303-11.
15. Fleming A, Jankowski J, Goldsmith P. In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study. Inflamm Bowel Dis 2010; 16: 1162-72.
16. Oehlers SH, Flores MV, Okuda KS, Hall CJ, Crosier KE, Crosier PS. A chemical enterocolitis model in zebrafish larvae that is dependent on microbiota and responsive to pharmacological agents. Dev Dyn 2011; 240: 288-98.
17. Marks L, Beard E, Cobey D, Moore N, Motyer V, Valentin JP, Ewart L. An evaluation of the non-invasive faecal pellet assessment method as an early drug discovery screen for gastrointestinal liability. J Pharmacol Toxicol 2013; 68: 123-36.
18. Abdu F, Hicks GA, Hennig G, Allen JP, Grundy D. Somatostatin sst(2) receptors inhibit peristalsis in the rat and mouse jejunum. Am J Physiol Gastrointest Liver Physiol 2002; 284: G624-33.
19. Keating C, Martinez V, Ewart L, Gibbons S, Grundy L, Valentin JP, Grundy D. The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions. Toxicol Appl Pharmacol 2010; 245: 299-309.
20. Peddyreddy MK, Dkhar SA, Ramaswamy S, Naveen AT, Shewade DG. An inherent acceleratory effect of insulin on small intestinal transit and its pharmacological characterization in normal mice. World J Gastroenterol 2006; 12: 2593-600.
21. Genschow E, Spielmann H, Scholz G, Seiler A, Brown N, Piersma A, Brady M, Clemann N et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 2002; 30: 151-76.
22. Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S, Martinez V, Pollard C et al. A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009; 60: 152-8.
23. Prior H, Ewart L, Bright J, Valentin JP. Refinement of the charcoal meal study by reduction of the fasting period. Altern Lab Anim 2012; 40: 99-107.
24. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
25. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003; 25: 2991-3026.
26. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72.
27. Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother 1996; 30: 158-64.
28. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1: 947-73.